PMID: 9433336Jan 20, 1998Paper

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

The American Journal of Psychiatry
J C BallengerIvan Gergel

Abstract

This study was designed to determine the minimum paroxetine dose effective for treating panic disorder. Of 425 patients with DSM-III-R panic disorder with or without agoraphobia who underwent a 2-week drug-free screening period, 278 patients were randomly assigned to double-blind treatment with a 10-week course of placebo or paroxetine at a dose of 10, 20, or 40 mg/day. At 40 mg/day, paroxetine was superior to placebo across the majority of outcome measures. Despite a mean of 9.5 to 11.6 full panic attacks during the screening period, 86.0% of the patients taking 40 mg of paroxetine, 65.2% of those taking 20 mg, 67.4% of those taking 10 mg, and 50.0% of the placebo-treated patients were free of full panic attacks during the 2 weeks ending at week 10. The 40-mg paroxetine group experienced significantly greater global improvement than the placebo group and significantly greater improvement in frequency of full and limited-symptom panic attacks, intensity of full panic attacks, phobic fear, anxiety, and depressive symptoms, usually evident by week 4. All doses of paroxetine were well tolerated, and adverse effects were consistent with those associated with selective serotonin reuptake inhibitors. Paroxetine is an effective and we...Continue Reading

Citations

Aug 17, 2000·Depression and Anxiety·R M Hirschfeld
Jul 27, 2001·Current Psychiatry Reports·M H Rapaport, C Barrett
Dec 4, 2001·The British Journal of Psychiatry : the Journal of Mental Science·D MichelsonS C Pemberton
May 25, 2002·CNS Drugs·Antona J WagstaffKaren L Goa
Oct 31, 2002·Human Psychopharmacology·Johan A. Den BoerBernhard R. Slaap
Nov 29, 2002·Human Psychopharmacology·Michel Bourin, Olivier Lambert
Dec 20, 2002·International Clinical Psychopharmacology·M SarchiaponeG Ferrari
Feb 22, 2003·CNS Drug Reviews·Udo Bonnet
Apr 17, 2004·Clinical Pharmacokinetics·Catherine C Crone, Geoffrey M Gabriel
Sep 28, 2004·CNS Spectrums·Borwin Bandelow, Eckart Rüther
Feb 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Arif KhanWalter A Brown
Feb 1, 2007·Neuropsychiatric Disease and Treatment·Martin A Katzman, Leslie Jacobs
Jul 29, 2010·Expert Review of Neurotherapeutics·Marina Dyskant Mochcovitch, Antonio Egidio Nardi
Sep 29, 2011·Perspectives on Psychological Science : a Journal of the Association for Psychological Science·Gregory A Miller
Jan 10, 2013·Annual Review of Clinical Psychology·Gregory A Miller, Brigitte Rockstroh
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Ian Anderson
Nov 28, 2018·Depression and Anxiety·Ewgeni JakubovskiMichael H Bloch
Feb 24, 2001·Journal of Clinical Psychopharmacology·M H RapaportR Wolkow
Feb 6, 1999·Journal of Clinical Psychopharmacology·R C RosenM Menza
Jan 9, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowUNKNOWN World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive
Apr 17, 2001·Depression and Anxiety·D L Dunner
Oct 1, 2004·Drugs·Michael Van AmeringenMark Bennett
Nov 8, 2005·Journal of Psychopharmacology·David S BaldwinUNKNOWN British Association for Psychopharmacology
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Apr 22, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Chi-Un PaeAshwin A Patkar
Aug 19, 2007·CNS Drugs·Giulio PerugiCristina Toni
Aug 16, 2008·The Mount Sinai Journal of Medicine, New York·Ellen J Hoffman, Sanjay J Mathew
Feb 13, 2009·Journal of Biopharmaceutical Statistics·Frank SchaarschmidtLudwig A Hothorn
Feb 23, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Kwan-Woo ChoiBum-Hee Yu
Jul 1, 2017·Zeitschrift Für Psychologie·Jessica I LakeGregory A Miller
Jul 16, 2019·Journal of Psychopharmacology·Laiana A QuagliatoUNKNOWN International Task Force on Benzodiazepines
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
Jul 15, 2000·Clinical Neuropharmacology·G CatalanoM C Catalano
Feb 10, 2004·CNS Spectrums·Mark H PollackUNKNOWN World Council of Anxiety
Jun 23, 2001·CNS Drug Reviews·M BourinY Guillon
Nov 26, 2003·The Australian and New Zealand Journal of Psychiatry·UNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphob
Mar 24, 2006·Expert Opinion on Pharmacotherapy·Gabriele MasiStefania Millepiedi
Jun 6, 2000·Issues in Mental Health Nursing·D Antai-Otong
Aug 29, 2002·Acta Psychiatrica Scandinavica·A BakkerP Spinhoven

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.